Printer Friendly

World Cancer Diagnostics Market 2014: Emerging Tests, Technology Assessment, Instrumentation Review, Sales Forecasts by Country and Strategic Profiles of Leading Suppliers.

NEW YORK, Jan. 15, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

World Cancer Diagnostics Market 2014: Emerging Tests, Technology Assessment, Instrumentation Review, Sales Forecasts by Country and Strategic Profiles of Leading Suppliers utm_campaign=In_Vitro_Diagnostic

This new report from Venture Planning Group provides analysis of the global cancer diagnostics market, including emerging tests, technologies, instrumentation, sales forecasts by country, and strategic profiles of leading suppliers.

The report presents: Estimated numbers of cancer testing laboratories, as well as test volume and sales forecasts for France, Germany, Italy, Japan, Spain, U.K. and U.S. Marketing and technological assessment, as well as medical rationale and diagnostic prospects for major categories of circulating and cellular tests, such as Biochemical Markers, Oncogenes, Growth Factors, Hormones, Colony Stimulating Factors, Lymphokines, Immunohistochemical Stains and others.

Overview of the clinical significance and market needs for both current and emerging cancer diagnostic tests, as well as listings of companies, universities and research centers developing or marketing new technologies, products, and applications.

Review of current instrumentation used for cancer diagnostic testing. Assessment of monoclonal antibodies, immunoassays, DNA probes, biochips/microarrays, chromosome analysis, IT, flow cytometry, biosensors, and their potential applications for cancer diagnostic testing. Competing/complementing technologies, such as CT, MRI, NMR, PET and photonics spectroscopy. Profiles of current and emerging suppliers of cancer diagnostic products, including their sales, product portfolios, distribution tactics, technological know-how, new products in R&D, collaborative arrangements and business strategies.

Contains 510 pages and 31 tables I. Worldwide Business Environment II. Worldwide Market Structure III. Major Current And Emerging Cancer Diagnostic Tests 1. Introduction 2. Tumor Marker Classification 3. ACTH 4. Alpha-Fetoprotein (AFP) 5. Beta-2 Microglobulin 6. CA 15-3/27.29 7. CA 19-9 8. CA-125 9. Calcitonin 10. Carcinoembrionic Antigen (CEA) 11. Estrogen and Progesterone Receptors 12. Ferritin 13. Gastrin 14. Human Chorionic Gonadotropin (HCG) 15. Insulin 16. NSE 17. Occult Blood

18. PAP Smear/HPV 19. Prostatic Acid Phosphatase (PAP) 20. Prostate-Specific Antigen (PSA) 21. Squamous Cell Carcinoma Antigen (SCC) 22. T and B Lymphocytes 23. TdT 24. Thyroglobulin 25. Tissue Polypeptide Antigen (TPA) 26. Biochemical Tumor Markers - ADA - B-Protein - PNP - 5'-Nucleotidase 27. Oncogenes - Abl/abl-bcr - AIB1 - BCL-2 - BRCA1 - CD44 - C-fos - C-myb

- C-myc - CYP-17 - Erb-B - HPC1 - N-myc - P40 - P51 - P53 - PIK3CA - PTI-1 - Ras - Reg - Sis - Src 28. Polypeptide Growth Factors - Basic Fibroblast Growth Factor - Beta-TGF - Cachectin (TNT) - Calmodulin - ECFR - Nerve Growth Factor (NGF) - Epidermal Growth Factor (EGF) - Ornithine Decarboxylase - Transferrin - Transforming Growth Factor-Alpha 29. Ectopic Hormones 30. Colony Stimulating Factors

31. Lymphokines - Alpha-Interferon - B Cell Growth Factors - B Cell Growth Factor (BCGF) - Gamma-Interferon - Interleukin-1 (IL-1) - Macrophage Activating Factor 32. Immunohistochemical Stains 33. Emerging Tumor Markers - N-Acetylglucosamine - Actin - Alpha-Actin - Antineuronal Antibodies - 7B2 - B72.3 - Bax - BCD-F9 - BLCA-4 - Blood Group Antigens A,B,H - CA 50 - CA 72-4/TAG-72 - CA 195 - CA-242 - CA-549 - CAM 26 - CAR-3 - Cathepsin-D

- Chromogranin A and B - Cluster 1 Antigen - Cluster-5/5A Antigen - CTA - CU18 - DR-70 - DU-PAN-2 - Endometrial Bleeding Associated Factor - Endostatin - Epithelial Membrane Antigen - Feulgen Hydrolysis - Fibronectin - FSH - (1->3)-L-fucosyltransferase - Gastrin-Releasing Peptide (GRP) - GDCFP-15 - Glucagon - Glycoamines - H23 - Her-2 - Human Carcinoma Antigen - HPA - HSP27 - Intermediate Filaments - Cytokeratins/CK18/Cyfra 21-1 - Desmin - Gliofibrillary Acid Protein - Neurofilaments

- Vimentin - KA 93 - Kinases - KP16D3 - LAI - Leukocyte Common Antigen - Lewis Antigens - Lysophosphatidic Acid (LPA) - Ma 695/Ma 552 - MABDF3 - MAG - ME1 - Minactivin - MN/CA9 - MSA - Mucin Cancer Antigen (MCA) - Multiple Tumor Suppressor 1 - Myosin - NEA-130 - NMP22

- OA-519 - Opiod Peptides - P-glycoprotein - Pancreatic Oncofetal Antigen (POA) - Placental Lactogen - PR92 - Proliferative Index, Ki-67 - Px - RB Inactivation/Deletion - Ret - SCCL 175 - Selectin - Sialic Acid - Sialyl SSEA-1/SLX - SN10 - Somatostatin - TA-90 - TABA - Tachykinin - TAG 12 - TPS - Troponin - Tubulin - VCAM - VEGF

- Villen IV. Instrumentation Review: Leading Analyzers Marketed by Abbott, Beckman Coulter/Danaher, Binding Site, bioMerieux, Carolina Chemistries, DiaSorin, Horiba, Inverness/Alere, J&J, Olympus, Roche, Siemens, Tosoh, Vital Diagnostics and other suppliers V. Current and Emerging Technologies 1. Monoclonal and Polyclonal Antibodies 2. Immunoassays a. Technological Principle b. Radioimmunoassay (RIA) c. Enzyme Immunoassays (EIA) - Overview - ELISA - Immunofiltration - Particle-Membrane Capture Immunoassay - Enzyme Amplification d. Fluorescent Immunoassays e. Luminescence - Chemiluminescence - Bioluminescence f. Latex Agglutination g. Immunoprecipitation H. Affinity Chromatographu e. Liposome Flow-Injection Immunoassay 3. Molecular Diagnostics a. Technology Overview

b. Amplification Methods - PCR - DAP-PCR - Immuno-PCR - QC-PCR - CAR - DNA - HPA - LCR - NASBA - QBR - SDA - 3 SR, and others 4. Chromosome Analysis a. Chronic Myelogenous Leukemia (CML) b. Acute Myeloid Leukemia (AML) c. Acute Lymphoblastic Leukemia (ALL) d. Malignant Lymphomas Lymphoid Malignancies e. Chronic Lymphocytic Leukemia (CLL) f. Solid Cancers g. Chromosomal Translocation and Oncogenes 5. Artificial Intelligence 6. Flow Cytometry 7. Two Dimensional Gel Electrophoresis (2-DGE) 8. Biosensors 9. Competing/Complementing Technologies a. CT b. MRI c. NMR d. PET e. Photonics Spectroscopy VI. Competitive Profiles - Abbott - AdnaGen - Applied Gene Technologies

- Beckman Coulter/Danaher - Becton Dickinson - Biomedical Diagnostics - bioMerieux - Bio-Rad - CellSearch - Cepheid - Dako - Decode - Diadexus - Diagnocure - Diasorin - Eiken Chemical - Enterix - Enzo Biochem - Epigenomics - Exact Sciences - Fujirebio - Gen-Probe - Guided Therapeutics - Hologic - Kreatech - Kyowa Medex - Life Technologies - Mackay Life Sciences - Myriad Genetics - Nanogen Elitech

- Nuvelo - OncoLab - Ortho-Clinical Diagnostics - Panacea Pharmaceuticals - Polartechnics - Polymedco - PreMD - Qiagen/Ipsogen - Radient Pharmaceuticals - Roche - Scienion - Sequenom - Siemens Healthcare - Takara Bio - Targeted Diagnostics & Therapeutics - Tosoh - Vermillion/Correlogic Systems - Wako Pure Chemicals - Wallac/PE - Zila

Appendixes: Major Universities and Research Centers Developing Cancer Diagnostic Technologies and Applications

List of Tables Tumor Marker Classification Major Companies Developing or Marketing ACTH Tests Major Companies Developing or Marketing AFP Tests Major Companies Developing or Marketing Beta-2 Microglobulin Tests Major Companies Developing or Marketing CA 15-3/27.29 Tests Major Companies Developing or Marketing CA 19-9 Tests Major Companies Developing or Marketing CA 125 Tests Major Companies Developing or Marketing Calcitonin Tests Major Companies Developing or Marketing CEA Tests Major Companies Developing or Marketing Estrogen Receptor Tests Major Companies Developing or Marketing Progesterone Receptor Tests Major Companies Developing or Marketing Ferritin Tests Major Companies Developing or Marketing Gastrin Tests Major Companies Developing or Marketing HCG Tests Major Companies Developing or Marketing Insulin Tests

Major Companies Developing or Marketing NSE Tests Major Companies Developing or Marketing Occult Blood Tests Major Companies Developing or Marketing PAP Smear/HPV Tests Major Companies Developing or Marketing PAP Tests Major Companies Developing or Marketing PSA Tests Major Companies Developing or Marketing Lymphocyte Subclassification Tests Biochemical Markers Potential Applications In Cancer Diagnosis Oncogenes Potential Applications In Cancer Diagnosis Major Companies Developing or Marketing Oncogene Tests Growth Factors Potential Applications In Cancer Diagnosis Colony Stimulating Factors Potential Applications in Cancer Diagnosis Lymphokines Potential Applications In Cancer Diagnosis Immunohistochemical Stains Potential Applications in Cancer Diagnosis Worldwide, All Market Segments, Laboratories Performing Cancer Diagnostic Testing By Country Worldwide, All Market Segments, Cancer Diagnostic Test Volume Forecasts By Country Worldwide, All Market Segments, Cancer Diagnostics Sales Forecasts By Country

To order this report: World Cancer Diagnostics Market 2014: Emerging Tests, Technology Assessment, Instrumentation Review, Sales Forecasts by Country and Strategic Profiles of Leading Suppliers utm_campaign=In_Vitro_Diagnostic

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

SOURCE Reportlinker
COPYRIGHT 2014 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2014 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jan 15, 2014
Words:1369
Previous Article:Skyera Names Former Brocade CEO to Board of Directors.
Next Article:Innovations in Big Data Analytics (Technical Insights).
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters